Single agent lorigerlimab demonstrated encouraging preliminary clinical activity in clear cell gynecologic cancer (CCGC) with a confirmed ORR of ...
A retrospective single-center cohort of 128 patients associated frontline bevacizumab with longer overall survival in ...
Amplia Therapeutics has advanced its cancer drug narmafotinib across four trials, with data suggesting it may work independently of common tumour-causing KRAS gene mutations.
A Brazilian study finds that abnormal p53 expression identifies recurrence risk in non-invasive high-grade endometrial cancer ...
Data Update demonstrates significant clinical benefit and survival improvements in advanced, chemoresistant sarcomas, ...
ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor ...
An AI model created by researchers at King's can detect signs of faulty repair mechanisms in ovarian cancer cells, potentially leading to a low-cost, widely accessible diagnostic tool in the future.
Maximize ROI through biomarker-led therapies, priority-market expansion, optimized resource allocation, and strategic co-development or acquisitionsDublin, Oct. 09, 2026 (GLOBE NEWSWIRE) -- "Low Grade ...
HRDPath, an AI model, analyzes tissue images to identify ovarian cancers with homologous recombination deficiency.
Cancer research is a rapidly progressing field, and encompasses a range of disciplines, including basic and translational ...
BioInvent reported updated Phase 1/2 data from Part B of its ongoing study of BI-1808 combined with pembrolizumab in heavily pretreated, platinum-resistant recurrent ovarian cancer, showing a 24% ...
Single-cell profiling at diagnosis can identify which patients with an aggressive form of ovarian cancer are likely to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results